SCHEMBL17834597

SCHEMBL17834597

Cc1ccc(-c2ccc(-c3cnc(-c4ccc(C[C@H](NC(=O)c5ccc(C(C)(C)C)s5)C(=O)N5CC(C(=O)O)C5)cc4)nc3)c(F)c2)c(F)c1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 5/20 0.34
ALOX5AP P20292 4/20 0.34
PYGL P06737 1/20 0.34
S1PR1 P21453 4/20 0.34
DPP4 P27487 1/20 0.34
S1PR3 Q99500 1/20 0.34
PRSS1 P07477 1/20 0.33
TMPRSS15 P98073 1/20 0.33
CTSA P10619 1/20 0.33
ITGB1 P05556 3/20 0.33
ITGA5 P08648 3/20 0.33
ITGB3 P05106 2/20 0.33
ITGAV P06756 2/20 0.33
ITGA2B P08514 2/20 0.33
ITGB5 P18084 2/20 0.33
KDM1A O60341 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17834881 0.96 S1PR1 (0.35) FEN1ALOX5APPYGLS1PR1DPP4
SCHEMBL17834419 0.96 S1PR1 (0.35) FEN1ALOX5APPYGLS1PR1DPP4
SCHEMBL17834612 0.94 PRSS1 (0.34) FEN1ALOX5APPYGLS1PR1DPP4
SCHEMBL17834449 0.94 FEN1 (0.40) FEN1ALOX5APPYGLS1PR1S1PR3
SCHEMBL17834412 0.93 DPP4 (0.36) FEN1ALOX5APPYGLDPP4PRSS1
SCHEMBL17995211 0.92 DPP4 (0.37) FEN1ALOX5APPYGLS1PR1DPP4
SCHEMBL19485716 0.92 ALOX5AP (0.42) FEN1ALOX5APITGB1
SCHEMBL22384272 0.92 ALOX5AP (0.37) FEN1ALOX5APPYGLDPP4PRSS1
SCHEMBL17834595 0.92 ITGB1 (0.37) PYGLITGB1ITGA5
SCHEMBL17834583 0.92 ALOX5AP (0.35) FEN1ALOX5APPYGLS1PR1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 EP disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R FEN1 3722/4885ALOX5AP 3115/4885PYGL 779/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R FEN1 3722/4885ALOX5AP 3115/4885PYGL 779/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR FEN1 3634/4885ALOX5AP 3438/4885PYGL 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.